Prodotto aggiunto correttamente al carrello.

discount label
H-KVVRFDKL-OH
Visualizzare in 3D

Biosynth logo

H-KVVRFDKL-OH

Rif. 3D-PP43742

1mg
202,00 €
10mg
234,00 €
100mg
412,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-KVVRFDKL-OH
Sinonimi:
  • NH2-Lys-Val-Val-Arg-Phe-Asp-Lys-Leu-OH
Descrizione:

Peptide H-KVVRFDKL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KVVRFDKL-OH include the following: IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice S Chen, X Wang, X Wu, MQ Wei, B Zhang, X Liu - Cellular , 2014 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0008874914001026 T cells compete for access to antigen-bearing antigen-presenting cells RM Kedl , WA Rees, DA Hildeman , B Schaefer - The Journal of , 2000 - rupress.orghttps://rupress.org/jem/article-abstract/192/8/1105/38929 The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS R Gavioli , S Cellini, A Castaldello, R Voltan - Vaccine, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X07013400 Processing of exogenous antigens for presentation by class I MHC molecules involves post-Golgi peptide exchange influenced by peptide-MHC complex stability and PJ Chefalo, CV Harding - The Journal of Immunology, 2001 - journals.aai.orghttps://journals.aai.org/jimmunol/article/167/3/1274/35053 An examination of the alternate MHC-I pathway: The source and nature of MHC-I complexes, peptide exchange and loading in acidified compartments PJ Chefalo - 2003 - search.proquest.comhttps://search.proquest.com/openview/3745c4f7b934bc20d304102f3726f6b3/1?pq-origsite=gscholar&cbl=18750&diss=y Exploring the structural elements of MHC-peptide-TCR interaction with analogs of VSV-8, an antigenic peptide derived from vesicular stomatitis virus NG Saito - 1998 - search.proquest.comhttps://search.proquest.com/openview/efc6c811698fb9d7244ceb7031b5b479/1?pq-origsite=gscholar&cbl=18750&diss=y Processing of Exogenous Antigens for IPGP Exchange - J Immunol, 2001 - academia.eduhttps://www.academia.edu/download/70425492/Processing_of_Exogenous_Antigens_for_Pre20210928-6834-8e9kjz.pdf Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance IA York , MA Brehm, S Zendzian - Proceedings of the , 2006 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0603095103 The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation IA York , AXY Mo, K Lemerise, W Zeng, Y Shen - Immunity, 2003 - cell.comhttps://www.cell.com/immunity/pdf/S1074-7613(03)00058-X.pdf Interferon γ limits the effectiveness of melanoma peptide vaccines HI Cho, YR Lee, E Celis - Blood, The Journal of the American , 2011 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/117/1/135/28755 Origin of Peptides Presented by MHC Class I Molecules: Generation by Proteasomes Precedes Evolution of the Immune System G Niedermann, K Eichmann - Symposium in Immunology VII: Vaccination, 1998 - Springerhttps://link.springer.com/content/pdf/10.1007/978-3-642-80466-3.pdf#page=12 Anti-Peptide Antibody Blocks Peptide E Reticulum - J Immunol, 2001 - researchgate.nethttps://www.researchgate.net/profile/Craig-Hilton/publication/12092680_Anti-Peptide_Antibody_Blocks_Peptide_Binding_to_MHC_Class_I_Molecules_in_the_Endoplasmic_Reticulum/links/5de01809a6fdcc2837f3d244/Anti-Peptide-Antibody-Blocks-Peptide-Binding-to-MHC-Class-I-Molecules-in-the-Endoplasmic-Reticulum.pdf Studying interactions involving the T-cell antigen receptor by surface plasmon resonance DH Margulies , D Plaksin, SN Khilko - Current opinion in , 1996 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0952791596800665 In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes D Nelson, C Bundell, B Robinson - The Journal of Immunology, 2000 - journals.aai.orghttps://journals.aai.org/jimmunol/article/165/11/6123/33687 Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector CS Bundell, C Jackaman , A Suhrbier - Cancer Immunology , 2006 - Springerhttps://link.springer.com/article/10.1007/s00262-005-0086-6 Immune Recognition and Editing of Tumours Expressing Multiple Antigenic Epitopes in Two Murine Models CS Bundell - 2006 - research-repository.uwa.edu.auhttps://research-repository.uwa.edu.au/files/3229331/Bundell_Christine_S_2006.pdf Anti-peptide antibody blocks peptide binding to MHC class I molecules in the endoplasmic reticulum CJ Hilton , AM Dahl, KL Rock - The Journal of Immunology, 2001 - journals.aai.orghttps://journals.aai.org/jimmunol/article/166/6/3952/70418 Anti-Peptide Antibody Blocks Peptide CJ Hilton , AM Dahl, KL Rock - scholar.archive.orghttps://scholar.archive.org/work/c72ogauyunfuhgex7k36gpd7w4/access/wayback/http://www.umassmed.edu/uploadedFiles/otm2/Ready_to_sign/00-32%20Ref.pdf CD8+ cytotoxic T cell responses to dominant tumor-associated antigens are profoundly weakened by aging yet subdominant responses retain functionality and C Jackaman , JK Gardner, F Tomay , J Spowart - , 2019 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2018.1564452 Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo C Jackaman , D Majewski, SA Fox , AK Nowak - Cancer Immunology , 2012 - Springerhttps://link.springer.com/article/10.1007/s00262-012-1307-4 Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides AXY Mo, SFL van Lelyveld, A Craiu - The Journal of , 2000 - journals.aai.orghttps://journals.aai.org/jimmunol/article/164/8/4003/32649

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP43742 H-KVVRFDKL-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".